# NAD+ vs NMN and NR: How the Precursors Differ | NAD+ > NAD+ vs NMN and NR: NAD+ is the coenzyme; NMN and NR are oral precursors the body converts into it. How the precursor routes differ in the research, and why oral products use them. Cited. NAD+ is the coenzyme; NMN and NR are the building blocks the body converts into it. The conversion routes, the human evidence for each, and why nearly every oral product is a precursor. ## Before the details Here is the whole comparison in three lines. NAD+ vs NMN is not a contest between two supplements — it is the difference between the *finished molecule* (NAD+, a coenzyme the cell uses for energy) and a *building block* (NMN, which the body converts into NAD+). NR is a second building block, a vitamin-B3 cousin that becomes NMN and then NAD+. Because the finished NAD+ molecule is large and hard to absorb whole, almost everything sold to "raise NAD+" is actually one of these precursors. This page sorts out which is which, using only what cited studies measured. ## Why Most Oral Products Are Precursors, Not NAD+ Itself NAD+ is a dinucleotide with two phosphate groups and a molecular weight of 663.43 Da — large, charged, and not freely taken up intact by most cells [8]. Swallowing the finished coenzyme is therefore an inefficient way to raise cellular NAD+, and most researchers consider precursors the rational oral approach [7]. A *precursor* is a smaller molecule the body converts into NAD+ through dedicated enzyme routes. The salvage pathway recycles nicotinamide into NAD+ via the rate-limiting enzyme NAMPT [5]. NR enters through a separate door — the NRK1/NRK2 kinase route, a Preiss-Handler-independent pathway first established in 2004 [6]. This is the biochemical reason a bottle labeled "NAD+" and a bottle of NMN or NR are not interchangeable. ## NMN (Nicotinamide Mononucleotide) in Human Trials NMN sits one biochemical step from NAD+. In a multicenter, double-blind, placebo-controlled RCT, oral NMN at 300, 600, and 900 mg/day for 60 days raised blood NAD+ at all doses versus placebo (p≤0.001) and improved walking distance, with 600 mg/day identified as the optimal dose and no safety issues at any dose [3]. A separate Science trial tested a lower dose: 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women, though body composition and HbA1c did not change [1]. Long-term NMN in mice suppressed age-associated weight gain rather than causing it. NMN's regulatory status as a supplement is contested in the US, as covered on the [NAD supplement research](/nad-supplement) page. ## Nicotinamide Riboside (NR): The Most-Studied Oral Precursor NR is the most clinically characterized oral NAD+ booster. In a randomized, double-blind, placebo-controlled trial of healthy overweight adults, NR raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day over 8 weeks — a clean dose-response — with no flushing and no significant adverse-event difference from placebo, and no elevation of LDL cholesterol [4]. NR's mechanism is well defined: it is converted to NMN by the NRK kinases and then to NAD+, the route established in 2004 [6]. In animal models, NR has shown protective effects in specific tissues — for example, given before noise exposure it preserved cochlear ribbon synapses and aided hearing recovery in mice [14]. These are preclinical findings, reported as what the studies measured. ## NMN and NR side by side Where do they differ that matters? Both are precursors that raise blood NAD+ in randomized human trials, and both are well tolerated at the doses studied [3][4]. NR is one biochemical step further upstream than NMN: it is phosphorylated by the NRK kinases into NMN, which is then adenylylated into NAD+ [6]. NMN sits directly adjacent to NAD+. NR has the larger and longer controlled human dataset, including the clean 22%/51%/142% dose-response [4], while NMN has the multicenter dose-finding RCT that named 600 mg/day as optimal [3]. The routes are also less private than they look. Isotope tracing in mice showed NAD+ precursors cycle between host tissues and the gut microbiome, with oral NR reaching host NAD+ partly via microbial conversion to nicotinic acid [12]. So "NMN versus NR" is a comparison of two well-characterized on-ramps to the same coenzyme, not a contest with a settled human winner — and neither is NAD+ itself. ## Is NAD just vitamin B3? Not quite. NAD+ is *built from* vitamin-B3-family precursors — niacin, nicotinamide, and nicotinamide riboside — but NAD+ itself is a larger dinucleotide coenzyme, not a vitamin [8]. NR is the B3-family precursor most associated with NAD+ supplementation because it feeds the dedicated NRK kinase route to NAD+ [6]. The niacin form enters by a different door again, the Preiss-Handler pathway [5]. So the vitamin B3 forms are inputs; NAD+ is the product. --- A color-coded poster wall of the NAD+ record — the coenzyme, its oral precursors NMN and NR, and the thin IV-therapy evidence each set in its own block and cited to the study that measured it, with the precursor-not-NAD+ distinction kept exact; no clinic behind the wall and nothing here dosed, compounded, prescribed, or sold.